WT-7695 has best-in-class properties for CA9 cancers

• BIC profile translated to greater in vivo tumor uptake, retention and efficacy
• 55 %IA/g delivered to tumor at 24 hours and 18 %IA/g retained at 7 days
• [¹⁷⁷Lu]LU-WT-7695 is 8-20x more efficacious in vivo than DPI-4452 & RAYZ-15710 (comparison based on published data)

Study in ccRCC mouse model (SK-RC-52)

SPR CA9 KD (nM)/off-rate (min)			Selectivity (X-fold)	%IA/g @ 18.3 MBq 177Lu		% Survival @ 80 days
Human	Mouse	Monkey	CA4/12/14	24h	7d	1.0-3 mCi
0.03/490	0.02/440	0.02/345	360/241/125	55%	18%	100%

 

To learn more, contact John Nagel.

See additional PDX imaging studies from Reinier Hernandez at the Targeted Radiopharmaceuticals Summit July 30-August 1.

Download the pitch deck